

GLAXOSMITHKLINE PLC

Form 6-K

January 11, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 11 January 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
 - b) Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019, on shares held through the Company's Share Reward Plan.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.2440	18

Aggregated information
 - d) Aggregated volume Price

n/a (single transaction)
 - e) Date of the transaction

2019-01-10
 - f) Place of the transaction

London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Vaccines
 - c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s)
 Aggregated information
 Price(s) Volume(s)
 £15.2440 65
- d) Aggregated volume Price n/a (single transaction)
- e) Date of the transaction 2019-01-10
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S Dingemans
- b) Position/status Chief Financial Officer
- c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument
 Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019, on shares held through the Company's Share Reward Plan.

- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £15.2440 24
- d) Aggregated information n/a (single transaction)

Aggregated volume Price

- e) Date of the transaction 2019-01-10
 f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr N Hirons
 b) Position/status SVP, Global Ethics & Compliance
 c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument
 ISIN: GB0009252882
- b) Nature of the transaction
 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019, on shares held through the Company's Share Reward Plan.
- | | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £15.2440 | 11 |
- Aggregated Information
- d) Aggregated volume Price n/a (single transaction)
- e) Date of the transaction 2019-01-10
 f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr L Miels
 b) Position/status President, Global Pharmaceuticals
 c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc

- b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each ('Ordinary Shares')

- a) Description of the financial instrument

ISIN: GB0009252882

- b) Nature of the transaction

Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 10
 January 2019, on shares held
 through the Company's Share
 Reward Plan.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£15.2440	3

Aggregated information

- d) Aggregated volume Price

n/a (single transaction)

- e) Date of the transaction

2019-01-10

- f) Place of the transaction

London Stock Exchange
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D S Redfern
 b) Position/status Chief Strategy Officer
 c) Initial notification/amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
 instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

Ordinary shares of 25 pence
 each ('Ordinary Shares')

- a) Description of the Financial instrument

ISIN:GB0009252882

- b) Nature of the transaction

Acquisition of Ordinary
 Shares following the
 re-investment of dividends
 paid to shareholders on 10
 January 2019, on shares held
 through the Company's Share
 Reward Plan.

c) Price(s) and volume(s)	Price(s)	Volume(s)
Aggregated information	£15.2440	73
d) Aggregated volume Price	n/a (single transaction)	
e) Date of the transaction	2019-01-10	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr R Simard
b) Position/status	President, Pharmaceutical Supply Chain
c) Initial notification/amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the Financial instrument	ISIN: GB0009252882
--	--------------------

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019, on shares held through the Company's Share Reward Plan.
------------------------------	--

c) Price(s) and volume(s)	Price(s)	Volume(s)
Aggregated information	£15.2440	19

d) Aggregated volume Price	n/a (single transaction)	
----------------------------	--------------------------	--

e) Date of the transaction	2019-01-10	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms C Thomas
b) Position/status	SVP, Human Resources

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the Financial instrument
- ISIN: GB0009252882
- b) Nature of the transaction
- Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| £15.2440 | 73 |
| n/a (single transaction) | |
- d) Aggregated information
- Aggregated volume Price
- e) Date of the transaction 2019-01-10
- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr P C Thomson
- b) Position/status President, Global Affairs
- c) Initial notification/amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')
- a) Description of the financial instrument
- ISIN: GB0009252882
- b) Nature of the transaction
- Acquisition of Ordinary Shares following the re-investment of dividends

paid to shareholders on 10 January 2019, on shares held through the Company's Share Reward Plan.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.2440	41
Aggregated information	n/a (single transaction)	
d) Aggregated volume Price		
e) Date of the transaction	2019-01-10	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mrs V A Whyte
b) Position/status	Company Secretary
c) Initial notification/amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument

ISIN: GB0009252882

b) Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019, on shares held through the Company's Share Reward Plan.

c) Price(s) and volume(s)	Price(s)	Volume(s)
	£15.2440	52
Aggregated information	n/a (single transaction)	
d) Aggregated volume Price		
e) Date of the transaction	2019-01-10	
f) Place of the transaction	London Stock Exchange (XLON)	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: January 11, 2019

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc